Drug Profile
Risperidone controlled-release implant - Braeburn Pharmaceuticals
Alternative Names: BB0817; EN 3342Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Endo Pharmaceuticals
- Developer Braeburn Pharmaceuticals
- Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 27 Sep 2021 Discontinued - Phase III for Schizophrenia in USA (SC)
- 06 Dec 2018 Braeburn Pharmaceuticals terminates a phase II trial in Schizophrenia in USA (SC) due to IND inactivation (NCT02658357)
- 26 Apr 2017 Adverse events, efficacy, pharmacokinetics data from a phase II trial in Schizophrenia released by Braeburn Pharmaceuticals